Semaglutide is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Semaglutide is the active ingredient of these drugs:
Australia Austria Brazil Canada Cyprus
Brazil Canada Estonia Finland Ireland
Canada Estonia Lithuania Poland United States
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):